MARC details
000 -LEADER |
fixed length control field |
03501nam a22005417a 4500 |
008 - FIXED-LENGTH DATA ELEMENTS--GENERAL INFORMATION |
fixed length control field |
171017s20182018 xxu||||| |||| 00| 0 eng d |
022 ## - INTERNATIONAL STANDARD SERIAL NUMBER |
International Standard Serial Number |
0736-4679 |
040 ## - CATALOGING SOURCE |
Original cataloging agency |
Ovid MEDLINE(R) |
099 ## - LOCAL FREE-TEXT CALL NUMBER (OCLC) |
PMID |
28987311 |
245 ## - TITLE STATEMENT |
Title |
Advances in Diabetes Pharmacotherapy: An Update for the Emergency Provider. |
251 ## - Source |
Source |
Journal of Emergency Medicine. 54(1):73-80, 2018 Jan. |
252 ## - Abbreviated Source |
Abbreviated source |
J Emerg Med. 54(1):73-80, 2018 Jan. |
252 ## - Abbreviated Source |
Former abbreviated source |
J Emerg Med. , 2017 Oct 05 |
253 ## - Journal Name |
Journal name |
The Journal of emergency medicine |
260 ## - PUBLICATION, DISTRIBUTION, ETC. |
Year |
2018 |
260 ## - PUBLICATION, DISTRIBUTION, ETC. |
Manufacturer |
FY2018 |
266 ## - Date added to catalog |
Date added to catalog |
2017-10-17 |
268 ## - Previous citation |
-- |
Journal of Emergency Medicine. , 2017 Oct 05 |
501 ## - WITH NOTE |
Local holdings |
Available online from MWHC library: 1995 - present, Available in print through MWHC library:1999-2007 |
520 ## - SUMMARY, ETC. |
Abstract |
BACKGROUND: Diabetes mellitus is a disease that affects millions of Americans, and its prevalence is only anticipated to increase in coming years. It is estimated that diabetes-related visits account for 1% of all emergency department (ED) encounters. In recent years, there have been several new categories of medications approved for the treatment of diabetes, including new insulins, glucagon-like peptide-1 receptor agonists, dipeptidyl peptidase-4 inhibitors, an amylin analogue, and sodium-glucose cotransporter-2 inhibitors. |
520 ## - SUMMARY, ETC. |
Abstract |
CONCLUSIONS: Emergency providers will encounter patients taking these newly approved medications, as well as treat those presenting with adverse effects and overdoses from them. As such, emergency providers must have a basic understanding of these new therapies so that they can optimally care for diabetic patients. Copyright (c) 2017 Elsevier Inc. All rights reserved. |
520 ## - SUMMARY, ETC. |
Abstract |
DISCUSSION: Many of these new therapies have been incorporated as first- and second-line agents for the management of diabetes. Recently approved diabetes medications often have different mechanisms of action and adverse effect and overdose profiles compared to traditional agents, such as sulfonylureas and metformin. |
520 ## - SUMMARY, ETC. |
Abstract |
OBJECTIVE OF THE REVIEW: This review presents recently approved agents to treat diabetes, with a focus on basic mechanism, place in therapy, and toxicities the ED provider may encounter. |
546 ## - LANGUAGE NOTE |
Language note |
English |
650 ## - SUBJECT ADDED ENTRY--TOPICAL TERM |
Topical term or geographic name entry element |
*Diabetes Mellitus/dt [Drug Therapy] |
650 ## - SUBJECT ADDED ENTRY--TOPICAL TERM |
Topical term or geographic name entry element |
*Drug Therapy/td [Trends] |
650 ## - SUBJECT ADDED ENTRY--TOPICAL TERM |
Topical term or geographic name entry element |
*Emergency Medicine/td [Trends] |
650 ## - SUBJECT ADDED ENTRY--TOPICAL TERM |
Topical term or geographic name entry element |
Dipeptidyl Peptidase 4/ag [Agonists] |
650 ## - SUBJECT ADDED ENTRY--TOPICAL TERM |
Topical term or geographic name entry element |
Dipeptidyl Peptidase 4/tu [Therapeutic Use] |
650 ## - SUBJECT ADDED ENTRY--TOPICAL TERM |
Topical term or geographic name entry element |
Glucagon-Like Peptide-1 Receptor/ai [Antagonists & Inhibitors] |
650 ## - SUBJECT ADDED ENTRY--TOPICAL TERM |
Topical term or geographic name entry element |
Glucagon-Like Peptide-1 Receptor/tu [Therapeutic Use] |
650 ## - SUBJECT ADDED ENTRY--TOPICAL TERM |
Topical term or geographic name entry element |
Humans |
650 ## - SUBJECT ADDED ENTRY--TOPICAL TERM |
Topical term or geographic name entry element |
Insulin Glargine/pd [Pharmacology] |
650 ## - SUBJECT ADDED ENTRY--TOPICAL TERM |
Topical term or geographic name entry element |
Insulin Glargine/tu [Therapeutic Use] |
650 ## - SUBJECT ADDED ENTRY--TOPICAL TERM |
Topical term or geographic name entry element |
Insulin, Long-Acting/pd [Pharmacology] |
650 ## - SUBJECT ADDED ENTRY--TOPICAL TERM |
Topical term or geographic name entry element |
Insulin, Long-Acting/tu [Therapeutic Use] |
650 ## - SUBJECT ADDED ENTRY--TOPICAL TERM |
Topical term or geographic name entry element |
Islet Amyloid Polypeptide/an [Analysis] |
650 ## - SUBJECT ADDED ENTRY--TOPICAL TERM |
Topical term or geographic name entry element |
Islet Amyloid Polypeptide/tu [Therapeutic Use] |
650 ## - SUBJECT ADDED ENTRY--TOPICAL TERM |
Topical term or geographic name entry element |
Sodium-Glucose Transporter 2/ai [Antagonists & Inhibitors] |
650 ## - SUBJECT ADDED ENTRY--TOPICAL TERM |
Topical term or geographic name entry element |
Sodium-Glucose Transporter 2/tu [Therapeutic Use] |
651 ## - SUBJECT ADDED ENTRY--GEOGRAPHIC NAME |
Institution |
MedStar Washington Hospital Center |
656 ## - INDEX TERM--OCCUPATION |
Department |
Emergency Medicine |
657 ## - INDEX TERM--FUNCTION |
Medline publication type |
Journal Article |
700 ## - ADDED ENTRY--PERSONAL NAME |
Local Authors |
Mazer-Amirshahi, Maryann |
790 ## - Authors |
All authors |
Mazer-Amirshahi M, Pourmand A |
856 ## - ELECTRONIC LOCATION AND ACCESS |
DOI |
<a href="https://dx.doi.org/10.1016/j.jemermed.2017.08.024">https://dx.doi.org/10.1016/j.jemermed.2017.08.024</a> |
Public note |
https://dx.doi.org/10.1016/j.jemermed.2017.08.024 |
942 ## - ADDED ENTRY ELEMENTS (KOHA) |
Koha item type |
Journal Article |
Item type description |
Article |